Replimune Sets Tudriqev's List Price at $450,000 Per Treatment Course

Introduction

Replimune has set the U.S. list price for its newly approved melanoma therapy Tudriqev at approximately $450,000 per treatment course, putting the drug among the higher-priced oncology therapies entering the market.

The pricing announcement comes shortly after the U.S. Food and Drug Administration (FDA) granted Tudriqev accelerated approval for use in combination with nivolumab (Opdivo) in adults with unresectable advanced cutaneous melanoma whose disease has progressed following an anti-PD-1-based treatment. The approval marks Replimune's first commercial product and a major transition for the biotechnology company from clinical development to commercialization.

$450,000 Price Tag for a Full Treatment Course

Replimune's announced price represents the expected cost of a complete course of Tudriqev treatment in the United States. According to reports, the company expects shipments of the therapy to begin approximately 60 days after approval.

The $450,000 price is the drug's list price and does not necessarily represent what individual patients or insurers will ultimately pay. Actual costs can vary depending on insurance coverage, negotiated discounts, reimbursement arrangements, and patient assistance programs.

For Replimune, establishing a high list price reflects the company's positioning of Tudriqev as an innovative oncology therapy for a patient population with limited treatment options after previous immunotherapy.

Tudriqev's Role in Advanced Melanoma

Tudriqev, also known by its development name RP1, is an oncolytic immunotherapy based on a genetically modified herpes simplex virus. It is injected directly into tumors and is designed to destroy cancer cells while stimulating an immune response that may help target cancer cells elsewhere in the body.

The FDA approved Tudriqev in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who have experienced disease progression following an anti-PD-1 antibody-based regimen.

The approval was based on results from the IGNYTE study, which enrolled 140 patients. Among the 91 patients in the efficacy-evaluable population with at least one non-injected lesion, the combination produced an objective response rate of 24.2%, with a median duration of response of 14.1 months.

A Major Commercial Milestone for Replimune

The launch of Tudriqev represents a significant change in Replimune's business profile. The company had previously operated primarily as a clinical-stage biotechnology company focused on developing oncolytic immunotherapies.

With FDA approval, Replimune now has the opportunity to generate commercial revenue from its lead therapy.

The company will also need to establish a commercial infrastructure covering manufacturing, distribution, healthcare-provider education, reimbursement support, and patient access. The ability to successfully execute these activities will be critical to translating regulatory approval into sustainable sales.

Pricing Comes After a Difficult Regulatory Journey

Tudriqev's commercial launch follows an unusually difficult regulatory path.

The therapy was previously rejected by the FDA twice before Replimune submitted the application for a third review. An FDA advisory committee subsequently voted 10–3 that the available efficacy data were evaluable and clinically meaningful.

The FDA then granted accelerated approval on August 6, 2026. The approval made Tudriqev Replimune's first approved product and ended a regulatory process that had attracted significant attention across the biotechnology industry.

How Tudriqev Fits Into the Competitive Landscape

Tudriqev enters a melanoma market that already includes established immunotherapies and newer treatment approaches.

One potential differentiating factor is its administration method. Unlike some advanced melanoma treatments that may require complex surgical procedures, Tudriqev is administered by injection directly into tumors. This could allow the therapy to reach a broader group of patients whose tumors are suitable for injection.

Replimune will nevertheless face the challenge of convincing physicians, hospitals, insurers, and patients of the treatment's value at a list price of $450,000 per course.

The Importance of Reimbursement and Patient Access

A high list price makes reimbursement strategy particularly important.

Replimune will need to work with insurers and healthcare providers to establish access pathways for eligible patients. The company has also introduced patient-support initiatives intended to assist with treatment access, reimbursement, and financial support.

For oncology drugs, the list price alone does not determine the economic burden on patients or healthcare systems. Negotiated prices, insurance coverage, treatment administration costs, and patient assistance can all influence the final cost of therapy.

Accelerated Approval Means More Evidence Is Still Required

Although Tudriqev has reached the market, its accelerated approval carries an important condition: Replimune must conduct additional research to confirm the treatment's clinical benefit.

The company is conducting a confirmatory Phase III study, known as IGNYTE-3. The results will be important for establishing the long-term clinical value of Tudriqev and maintaining its regulatory position.

This creates an important balance for Replimune. The company can begin commercializing the therapy and generating revenue, but it must continue investing in clinical development and demonstrate that the treatment's benefits are confirmed in additional evidence.

Potential Commercial Opportunity

Despite the high price, Tudriqev could represent a significant commercial opportunity if Replimune successfully establishes the therapy as a standard option for eligible melanoma patients.

The company has identified a substantial population of patients whose melanoma progresses after immune checkpoint inhibitor treatment. Tudriqev's ability to be used across certain patient subgroups could expand its potential market.

Analysts have estimated that the drug could eventually generate substantial U.S. sales if adoption grows, although actual performance will depend on patient eligibility, physician adoption, reimbursement, competition, and confirmatory clinical results.

What the $450,000 Price Signals for Oncology

The launch price also reflects a broader trend in the pharmaceutical industry: innovative cancer therapies can command very high prices when they target serious diseases with limited treatment options.

However, increasingly high drug prices are also placing greater emphasis on value-based healthcare. Payers and healthcare systems are likely to scrutinize the relationship between a treatment's cost, clinical benefit, duration of response, and impact on patient outcomes.

For Tudriqev, demonstrating durable clinical benefit will therefore be important not only from a regulatory perspective but also from a commercial and market-access standpoint.

Conclusion

Replimune's decision to set Tudriqev's U.S. list price at $450,000 per treatment course marks an important milestone in the drug's transition from an experimental therapy to a commercial oncology product.

The price reflects the company's expectations for an innovative treatment aimed at patients with advanced melanoma who have progressed after anti-PD-1 therapy. However, the drug's commercial success will depend on more than its list price. Reimbursement, patient access, physician adoption, competition, and confirmatory clinical evidence will all play critical roles.

With Tudriqev now approved and commercialization underway, Replimune enters a new phase in which it must demonstrate that its innovative therapy can deliver both meaningful clinical value and sustainable commercial performance.